University of Washington) to identify and design more effective and safer therapeutics. The safety and efficacy of our lead compound, 4MT2001, have been demonstrated through in-human safety assessments and genetic target validation conducted by external researchers. These findings are further supported by our comprehensive in vitro and in vivo studies, which highlight its potential as a best-in-class treatment for bipolar disorder (BPD). BPD, a lifelong condition typically manifesting in the late teens to early 20s, affects approximately 7 million individuals in the U.S. The FDA has reviewed our program and provided feedback, enabling us to proceed with the initiation of Phase 1 clinical trials in early 2025. Our pipeline also includes potential breakthrough treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD), and other CNS disorders. We have raised over $5 million to date with all founders and board members participating.